Oral Nadolol for the Treatment of Adults With Mild Asthma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-01-31

Study Completion Date

2009-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to confirm previous observations in asthmatics that chronic nadolol treatment reduces asthmatic airway hyper-responsiveness.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma

NCT01804218

Mild Persistent Asthma, Uncomplicated

UNKNOWN PHASE2

Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study

NCT01196377

Acute Asthma

COMPLETED NA

Reversal of Acute β-Blocker Induced Bronchoconstriction

NCT01070225

Asthma

COMPLETED PHASE4

Beta Blockers for the Treatment of Asthma

NCT01074853

Asthma

COMPLETED PHASE2

Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma

NCT01316315

Asthma

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Open Label treatment with oral Nadolol

Dose escalation through 1.25mgs, 2.5mgs, 5.0mgs, 10mgs, 20mgs, and 40mgs of nadolol at 2 week intervals as tolerated.

Group Type EXPERIMENTAL

nadolol

Intervention Type DRUG

Nadolol, oral taken daily, doses will be escalated every two weeks over 13 weeks following a 2 week run-in.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nadolol

Nadolol, oral taken daily, doses will be escalated every two weeks over 13 weeks following a 2 week run-in.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Corgard

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pre-bronchodilator FEV1 80% or greater than the predicted value.
* PC20 FEV1 ≤4 mg/ml on methacholine challenge test.
* Blood Pressure ≥ 100/65mm Hg.
* Pulse rate ≥ 60 beats/min.
* No significant health issues.
* Non-smoker or X-smoker \< 10 pack/year.

Exclusion Criteria

* History of upper/lower respiratory tract infection or asthma exacerbation within 6 weeks of first baseline visit.
* Currently diagnosed with chronic obstructive pulmonary disease (COPD).
* Used any oral or inhaled corticosteroids within 4 weeks of the first baseline visit.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No